

**PCR-/NAT MRSA / cMRSA
 (RV 539) Nov 2020**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
2025391	+++	61 / 72	MRSA (<i>S. aureus</i> , PVL-neg, pSA442 neg.) (~1x10 ⁵ CFU/mL)
2025392	∅	62 / 73	CoNS <i>oxa^S</i> (~1x10 ³ CFU/mL)
2025393	+	61 / 71,72	cMRSA (<i>S. aureus</i> , <i>oxa^R</i> , PVL-pos) (~ 5x10 ³ CFU/mL)
2025394	++	61 / 71,72	cMRSA (<i>S. aureus</i> , <i>oxa^R</i> , PVL-pos) (~ 5x10 ⁴ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 277</i>	<i>Probennummer (Sample no.)</i>					<i>Inhibition</i>			
	2025391	2025392	2025393	2025394		2025391	2025392	2025393	2025394
<i>Befund Result</i>									
Positiv	250	5	273	275	n.d.	4	4	4	4
Negativ	24	272	3	2	nein no	273	273	273	273
Fraglich Questionable	3	0	1	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv <i>True positive results</i>						NAT richtig negativ	
	2025391		2025393		2025394		2025392	
	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%
Amplex eazyplex MRSA plus (n = 5)	4	80	5	100	5	100	5	100
BD MAX/ BD GeneOhm MRSA (n = 48)	48	100	47	97	48	100	45	94
HAIN FluoroType/ GenoType (n = 23)	17	74	22	96	23	100	23	100
Cepheid Xpert MRSA (n = 142)	141	99	140	99	140	99	140	99
Immundiagnostik MutaPLEX MRSA(n=3)	3	100	3	100	3	100	3	100
r-Biopharm RIDAGENE MRSA (n = 27)	11	41	27	100	27	100	27	100
Other commercial tests (n = 12)	11	92	12	100	12	100	12	100
<i>In house</i> PCR assay (n = 17)	15	88	17	100	17	100	17	100